Javascript must be enabled to continue!
Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design
View through CrossRef
AbstractA green, rapid, and simple RP-UPLC method was developed and optimized by full factorial design for the simultaneous separation of oseltamivir phosphate, daclatasivir dihydrochloride, and remdesivir, with dexamethasone as a co-administered drug. The separation was established on a UPLC column BEH C18 1.7 µm (2.1 × 100.0 mm) connected with a UPLC pre-column BEH 1.7 µm (2.1 × 5.0 mm) at 25 °C with an injection volume of 10 µL. The detector (PDA) was set at 239 nm. The mobile phase consisted of methanol and ammonium acetate (8.1818 mM) in a ratio of 75.7: 24.3 (v/v). The flow rate was set at 0.048 mL min−1. The overall separation time was 9.5 min. The retention times of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were 6.323 ± 0.145, 7.166 ± 0.036, 8.078 ± 0.124, and 8.572 ± 0.166 min (eight replicates), respectively. The proposed method demonstrated linearity in the ranges of 10.0–500.0 (ng mL−1) and 0.5–30.0 (µg mL−1) for oseltamivir phosphate, 50.0–5000.0 (ng mL−1) for dexamethasone, 25.0–1000.0 (ng mL−1) and 0.5–25.0 (µg mL−1) for daclatasvir dihydrochlorde, and 10.0–500.0 (ng mL−1) and 0.5–30.0 (µg mL−1) for remdesivir. The coefficients of determination (R2) were greater than 0.9999, with percentage recoveries greater than 99.5% for each drug. The limits of quantitation were 6.4, 1.8, 7.8, and 1.6 ng mL−1, and the limits of detection were 1.9, 0.5, 2.0, and 0.5 ng mL−1 for oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir, respectively. The proposed method was highly precise, as indicated by the low percentage of relative standard deviation values of less than 1.2% for each drug. The average content and uniformity of dosage units in the studied drugs' dosage forms were determined. The average contents of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were nearly 93%, 102%, 99%, and 95%, respectively, while the uniformity of dosage unit values were nearly 92%, 102%, 101%, and 97%. Two novel methods were established in this work. The first method was used to assess the stability of standard solutions. This novel method was based on the slope of regression equations. The second was to evaluate the excipient's interference using an innovative instrumental standard addition method. The novel instrumental standard addition method was performed using the UPLC instrument program. It was more accurate, sensitive, time-saving, economical, and eco-friendly than the classic standard addition method. The results showed that the proposed method can estimate the tested drugs' concentrations without interference from their dosage form excipients. According to the Eco-score (more than 75), the Green Analytical Procedure Index (GAPI), and the AGREE criteria (total score of 0.77), the suggested method was considered eco-friendly.
Springer Science and Business Media LLC
Title: Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design
Description:
AbstractA green, rapid, and simple RP-UPLC method was developed and optimized by full factorial design for the simultaneous separation of oseltamivir phosphate, daclatasivir dihydrochloride, and remdesivir, with dexamethasone as a co-administered drug.
The separation was established on a UPLC column BEH C18 1.
7 µm (2.
1 × 100.
0 mm) connected with a UPLC pre-column BEH 1.
7 µm (2.
1 × 5.
0 mm) at 25 °C with an injection volume of 10 µL.
The detector (PDA) was set at 239 nm.
The mobile phase consisted of methanol and ammonium acetate (8.
1818 mM) in a ratio of 75.
7: 24.
3 (v/v).
The flow rate was set at 0.
048 mL min−1.
The overall separation time was 9.
5 min.
The retention times of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were 6.
323 ± 0.
145, 7.
166 ± 0.
036, 8.
078 ± 0.
124, and 8.
572 ± 0.
166 min (eight replicates), respectively.
The proposed method demonstrated linearity in the ranges of 10.
0–500.
0 (ng mL−1) and 0.
5–30.
0 (µg mL−1) for oseltamivir phosphate, 50.
0–5000.
0 (ng mL−1) for dexamethasone, 25.
0–1000.
0 (ng mL−1) and 0.
5–25.
0 (µg mL−1) for daclatasvir dihydrochlorde, and 10.
0–500.
0 (ng mL−1) and 0.
5–30.
0 (µg mL−1) for remdesivir.
The coefficients of determination (R2) were greater than 0.
9999, with percentage recoveries greater than 99.
5% for each drug.
The limits of quantitation were 6.
4, 1.
8, 7.
8, and 1.
6 ng mL−1, and the limits of detection were 1.
9, 0.
5, 2.
0, and 0.
5 ng mL−1 for oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir, respectively.
The proposed method was highly precise, as indicated by the low percentage of relative standard deviation values of less than 1.
2% for each drug.
The average content and uniformity of dosage units in the studied drugs' dosage forms were determined.
The average contents of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were nearly 93%, 102%, 99%, and 95%, respectively, while the uniformity of dosage unit values were nearly 92%, 102%, 101%, and 97%.
Two novel methods were established in this work.
The first method was used to assess the stability of standard solutions.
This novel method was based on the slope of regression equations.
The second was to evaluate the excipient's interference using an innovative instrumental standard addition method.
The novel instrumental standard addition method was performed using the UPLC instrument program.
It was more accurate, sensitive, time-saving, economical, and eco-friendly than the classic standard addition method.
The results showed that the proposed method can estimate the tested drugs' concentrations without interference from their dosage form excipients.
According to the Eco-score (more than 75), the Green Analytical Procedure Index (GAPI), and the AGREE criteria (total score of 0.
77), the suggested method was considered eco-friendly.
Related Results
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
PERSEPSI IBU HAMIL TENTANG VAKSIN COVID-19 TERHADAP PELAKSANAAN VAKSINASI COVID-19
PERSEPSI IBU HAMIL TENTANG VAKSIN COVID-19 TERHADAP PELAKSANAAN VAKSINASI COVID-19
Latar Belakang: kasus positif Covid-19 di Kabupaten Sukoharjo tahun 2021 mencapai 12.350 dan terus mengalami penambahan jumlah. Dari jumlah tersebut terdapat 168 kasus positif Covi...
The Impact of the Covid-19 Pandemic and Macroeconomics on the Sharia Stock Indexes in Indonesia
The Impact of the Covid-19 Pandemic and Macroeconomics on the Sharia Stock Indexes in Indonesia
ABSTRACT
The Covid-19 pandemic has changed economic conditions in various countries, including Indonesia. One of the sectors affected is the capital market sector which can also de...
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID is the consequence of having had COVID. Long COVID has many other names including Long-haul COVID, Post-COVID conditions (PCC), Post-COVID-19 syndrome, Post-acute seque...

